Eli Lilly, one of the most important pharmaceutical companies, recently released topline Phase 3 results from a major clinical trial showing that Ret, a next-generation triple receptor agonist, produced unprecedented weight Loss and health improvements in adults with obesity and knee osteoarthritis.
Here’s everything you need to know about this incredible clinical data drop:
- Unmatched weight Loss: In the Triumph-4 Phase 3 trial, people taking the highest doses of RETA lost approximately 28.7% of their body weight (roughly 71 pounds for someone starting at 248 lbs) in just over a year. In context, the best currently approved weight-loss medications product approximately 15% to 20% average weight-loss in the same time frame, so this result is next level. The participants were regular obese people with no healthy habits. If they got such incredible results with no effort, what do you think would happen to someone who combines it with consistent exercise?
- This trial wasn’t just about weight. Many participants also had knee osteoarthritis, and Reta reduced pain scores by up to 76%, meaning less pain and better physical function. That’s especially meaningful because obesity and joint pain often feed into each other: Less weight leads to less stress on the joints leads to better mobility. Additionally, it was also reported improvements in blood pressure, cholesterol, triglycerides, and inflammatory markers. Earlier research also showed striking drops in liver fat up to 80+%, so it is a clear that the benefits of this compound go way beyond weight Loss
What you should know:
- These results are topline data, so full scientific papers are still pending peer-review and publication. Lilly has seven more Phase 3 trial underway.
- A minority of participants in the trial discontinued Reta due to side-effects like nausea or gastrointestinal issues (a fairly common pattern in this class of medications that can esily be mitigated by lowering doses).
- The magnitude of the results nearly 30% average weight loss plus pain relief is historically rare and points to the potentially paradigm-shifting therapy
This is not Medical Advice and for educational purposes only!
